NCT02747797View on ClinicalTrials.gov

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2017

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2022

Conditions
Advanced Cancer
Interventions
DRUG

Lucitanib

10 mg orally daily

Trial Locations (1)

92093

UC San Diego Moores Cancer Center, La Jolla

Sponsors

Collaborators (1)

Clovis Oncology, Inc.
All Listed Sponsors
collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

Teresa Helsten, MD

OTHER

NCT02747797 - Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations | Biotech Hunter | Biotech Hunter